Primary trials begin in Liberia for Ebola Vaccine

By Kate Hassett

Primary trials begin in Liberia for Ebola Vaccine
In the latest advancement in the fight against Ebola in West Africa, a trial vaccine has been delivered to a secret location in Liberia.

The vaccine, which contains small amounts of the virus, has been trialled on 12 volunteers and pending its response, will be administered to upwards of 27,000 more.

The vaccine aims at forcing the body to produce antibodies by administering a measured dose of the virus into willing participants.

Dr Steven Kennedy, the senior scientist at the forefront of the trials, explained that the vaccine contains a sample of the Zaire strain, which is unable to produce the Ebola virus in its participants and poses no threat to the volunteers.

As the results of the trials are yet to be identified, nurses in Liberia are being trained to monitor the reactions of participants over the coming months.

The GlaxoSmithKline vaccine is also undergoing simultaneous testing in Switzerland, UK, United States and Mali. The 200 volunteers involved in the trail have shown positive results and assured the safety of the initial candidate vaccine.

The World Health Organisation has stated the importance of committing to ongoing treatment and care; “The international response that has got us this point has been phenomenal and we must keep on course until the infection rate is brought down to, and remains at, zero.”

SHARE THIS ARTICLE

BECOME A MiNDFOOD SUBSCRIBER TODAY

Let us keep you up to date with our weekly MiNDFOOD e-newsletters which include the weekly menu plan, health and news updates or tempt your taste buds with the MiNDFOOD Daily Recipe.